APRE

Aprea Therapeutics, Inc.
CAPPED RATING

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.

Aprea Therapeutics, Inc. (APRE) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
D+
Factor Score 1.8 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.9
EV / EBITDA 2.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -39.6%
Price Return 12M -65.9%
Catalyst Signal 0.00
Market Cap $5.8M
TTM Revenue $3.3K
Price / Sales 1.7K
ROE -60.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 D+ (1.8) D+ (1.6) D (1.3) D+ (1.6) C+ (2.6) D+ (1.8)
2026-11-10 C- (1.9) D+ (1.8) D (1.3) D+ (1.8) C+ (2.6) C- (1.9)
2026-11-03 D+ (1.8) D+ (1.5) D (1.3) C (2.2) C+ (2.7) C- (1.9)
2026-10-27 D+ (1.8) D+ (1.5) D (1.3) C- (1.9) C+ (2.6) D+ (1.8)
2026-10-20 D+ (1.8) D+ (1.5) D (1.3) C- (1.9) C+ (2.6) D+ (1.8)
Page 1 of 6